Medina-Santillán R, Mateos-García E, Reyes-García G, Castañeda-Hernández G, Sotelo J

Language: Spanish
References: 16
Page: 203-208
PDF size: 46.39 Kb.

ABSTRACT

The effectiveness of the treatment of neurocysticercosis with praziquantel has been assessed in several clinical trials in the last 20 years. Most studies employed a dose of 50 mg/kg/day, three times at day during 2 weeks. Recently, a novel and brief dosage scheme of praziquantel has been described. This scheme employs three doses of 25 mg/kg, and all are administered separately on the same day, with interval of 2 hours. This scheme has a direct impact on direct costs (cost of drugs), with a 90% reduction of the traditional scheme. In addition to a favorable impact on direct costs, the impact on indirect costs is important: with the short-scheme, hospitalization in unnecessary, and costs of hospital visits for patient and family is avoided, with subsequent improvement of emotional status and family environment.

REFERENCES

1. 1. Del Brutto O, Sotelo J. Neurocysticercosis: an update. Rev Infect Dis 1988;10:1075-1087.

2. 2. Rabiela MT, Rivas MA, Rodríguez IF. Consideraciones anatomopatológicas sobre cisticercosis cerebral como causa de muerte. Patología Mex 1979;17:119-1136.

3. 3. Kalra V, Deorari AK, Goulatia RK. Praziquantel therapy in childhood neurocysticercosis. Indian Pediatr 1987. p. 1095-1098.

4. 4. Jung H, Medina R, Castro N, Corona T, Sotelo J. Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Antimicrob Agents Chemother 1997;41:1256-1259.

5. 5. Cruz M. Davis A. Dixon H, Pawlowski Z, Proano J. Operational studies on control of Taenia slim taeniasis/cysticercosis in Ecuador. Bull Who 1989;67:401-407.

6. 6. Soleto J, Jung H. Pharmacokinetic optimization of the treatment of neurocysticercosis. Clin Pharmacokinetic 1998;34:503-515.

7. 7. Bittencourt PR, Gracia CM, Gorz AM, et al. High-dose praziquantel for neurocysticercosis: serum and CSF concentrations. Acta Neurol Scand 1990;2:28-33.

8. 8. Overbosh D, Van de Nes J, Groh E, et al. Penetration of praziquantel into cerebrospinal fluid and cysticerci in human cysticercosis. Eur J Clin Pharmacol 1988;33:287-292.

9. 9. Corona T, Lugo R, Medina R, Sotelo J. Single-day praziquantel therapy for neurocysticercosis. N Engl J Med 1996;334:125.

10. Corona T, Lugo R, Medina R, Sotelo J. Esquema corto de praziquantel para el tratamiento de la neurocisticercosis parenquimatosa. Gac Med Mex 1999;135:369-373.

11. White AC Jr. Neurocysticercosis: a major cause of neurological disease worldwide. Clin Infect Dis 1997;24: 101-115.

12. Girgis NI, Farid Z, Mikhail IA, Farrag I, Sultan Y, Kilpatrick ME. Dexamethasone treatment for bacterial meningitis in children and adults. Pediatr Infect Dis 1989;8(12):848-851.

13. Ratka A, Erramouspe J. Intramuscular ceftriaxone in the treatment of childhood meningitis due to Haemophilus influenzae type F. Ann Pharmacother 2001;35(1):36-40.

14. Sotelo J, del Brutto OH, Escobedo F, Torres B, Rodriguez-Carbajal J, Rubio-Donnadieu F. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. J Neuro 1990;237:69-72.

15. Bittencourt PR, Gracia CM, Gorz AM, Mazaer S, Oliverira TV. High-dose praziquantel for neurocysticercosis: efficacy and tolerability. Eur Neurol 1990;30:229-234.

16. Spilker B, et al. Guide to clinical trials. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 1991. p. 302-312.